A comprehensive search of the literature on the electronic databases PubMed was conducted for the subject terms of GSK-3 and prostate cancer. Gene mutation and expression information was extracted from Oncomine and COSMIC databases. Case reports were not included.
Accumulating evidence indicates that GSK-3伪 is mainly expressed in low-risk prostate cancers and is related to hormone-dependent androgen receptor (AR)–mediated gene expression, whereas GSK-3尾 is mainly expressed in high-risk prostate cancers and is related to hormone-independent AR-mediated gene expression. GSK-3 has been demonstrated as a positive regulator in AR transactivation and prostate cancer growth independent of the Wnt/尾-catenin pathway. Different types of GSK-3inhibitors including lithium show promising results in suppressing tumor growth in different animal models of prostate cancer. Importantly, clinical use of lithium is associated with reduced cancer incidence in psychiatric patients.
Taken together, GSK-3 inhibition might be implicated in prostate cancer management as a preventive treatment.